In the recent weeks, Aptus Bioreactors has decided to partner with a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA Institute. ARMI brings together a consortium of over 100 partner organizations from industry, government, academia and the non-profit sector to develop the next-generation manufacturing processes and technologies for cells, tissues and organs.
Approximately $80 million from the federal government will be combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the United States, ARMI will lead BioFabUSA Institute on behalf of the Department of Defense.
Under the umbrella of Manufacturing USA, a public-private network that invests in the development of world-leading manufacturing technologies, ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue Biofabrication technology to better position the U.S. relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs.
“We need to develop 21st century tools for engineered tissue manufacturing that will allow these innovations to be widely available - similar to how a 15th century tool (the printing press) allowed knowledge to spread widely during the Renaissance,” said inventor Dean Kamen, ARMI’s chairman.
About Aptus Bioreactors
In partnering with ARMI, Aptus Bioreactors joins a network of like-minded research groups who are striving to expand upon the regenerative manufacturing industry. With supporting companies, educational opportunities, and additional marketing opportunities we believe that this partnership will push Aptus Bioreactors further towards our company vision of achieving “One Surgery, for Life” for patients with heart valve disease. To this end, patients who typically undergo several, costly medical treatments, including surgeries and drug therapies, would someday receive one, patient-specific heart valve replacement that could grow and develop during the course of their life without any further interventions.
For more information on ARMI, please visit www.ARMIUSA.org.
For more information on Aptus Bioreactors, please visit www.AptusBioreactors.com.
By: Madeline Blankenship